We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gene Therapy Cures Heart Disorder in Mouse Model

By Biotechdaily staff writers
Posted on 23 Aug 2006
Researchers have identified a subtype of the adeno-associated virus (AAV) that is 200 times more potent in its ability to penetrate cardiac tissue, and have demonstrated its potential for use in gene therapy by successfully treating a mouse model for Pompe disease. More...


Pompe disease (also called glycogen storage disease type II or acid maltase deficiency) is a rare genetic disorder caused by a deficiency in the enzyme acid alpha-glucosidase (GAA), which is needed to break down glycogen. It is the only glycogen storage disease with a defect in lysosomal metabolism and was the first glycogen storage disease to be identified.

The build-up of glycogen causes progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver, and nervous system. Transmission is by autosomal recessive inheritance. Children have a one in four chance of inheriting the disease when both parents carry the abnormal gene. It is estimated to occur in about one in 40,000-300,000 births.

Investigators at the University of Florida (Gainesville, USA) evaluated several different sub-types of AAV as potential vectors for gene therapy of congenital heart diseases. They found that the AAV-9 subtype was taken up throughout the heart muscle at 200 times the levels achieved with the previously used AAV-1 subtype. None of the AAV subtypes tested were found to cause disease or trigger a major immune system reaction.

The AAV-9 vector was loaded with the gene for GGA that is lacking in Pompe disease and then injected into animals in a mouse model for the syndrome. Results published in the July 27, 2006, online edition of Circulation Research revealed that the gene therapy eliminated symptoms of the disease.

"Right now AAV-9 seems to be our best solution for heart problems,” said senior author Dr. Barry J. Byrne, professor of pediatric cardiology at the University of Florida. "This is a way of delivering gene therapy to the heart that is aimed at treating genetic diseases affecting the heart. It is efficient and long lasting. One of the other distinguishing features of our research is that it is probably the first to demonstrate a physiologic correction of a genetic cardiac abnormality.”



Related Links:
University of Florida

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The POC diagnostic test aims to use fingerstick blood, serum, or plasma sample to detect typhoid fever (Photo courtesy of Adobe Stock)

POC Test Uses Fingerstick Blood, Serum, Or Plasma Sample to Detect Typhoid Fever

Typhoid fever is an acute febrile illness caused by Salmonella enterica serovar Typhi (S. Typhi) and affects an estimated 11–21 million people globally each year, resulting in approximately 128,000–161,000... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.